research use only

Trilaciclib CDK inhibitor

Name: Trilaciclib
Brand: Selleck Chemicals
SKU: S8389
Availability: InStock
Rating: 5 (4 reviews)

Cat.No.S8389

Trilaciclib is a highly potent, selective and reversible cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. This compound inhibits CDK4/cyclin D1 and CDK6/cyclin D3 with IC50 of 1 nM and 4 nM, respectively.

Chemical Structure

Molecular Weight: 446.55

Jump to

Quality Control

Batch: Purity: 99.55%

99.55

Related Targets	HSP PD-1/PD-L1 ROCK Wee1 DNA/RNA Synthesis Microtubule Associated Ras KRas Aurora Kinase Casein Kinase
Other CDK Inhibitors	AS2863619 Ro-3306 SEL120 (SEL120-34A) hydrochloride INX-315 Tagtociclib (PF-07104091) PF-07220060 (CDK4/6-IN-6) AZD4573 ON123300 Enitociclib (BAY 1251152) Samuraciclib (ICEC0942) hydrochloride

Solubility

In vitro
Batch:

DMSO : 2 mg/mL (4.47 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
	5%0.1MHCL 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.150mg/ml (0.34mM)

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	446.55	Formula	C₂₄H₃₀N₈O	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	1374743-00-6	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	G1T28, G1T28-1			SMILES	CN1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	CDK4/cyclin D1 (Cell-free assay) 1 nM CDK6/cyclin D3 (Cell-free assay) 4 nM
In vitro	Trilaciclib is a potent and selective CDK4/6 inhibitor that inhibits the phosphorylation of RB and induces an exclusive, reversible G1 arrest. In vitro and in vivo, this compound protects RB competent cells from damage by chemotherapy as assessed by gamma-H2A.X (γH2AX) and apoptosis through caspase 3/7 activation.
In vivo	In vivo, this compound regulates the proliferation of HSPCs in both mouse and canine bone marrow, in a reversible, doseand time-dependent manner. Pretreatment of mice with this compound allows a faster recovery of complete blood counts (CBCs) following chemotherapy. In addition, it does not protect RB deficient tumors from chemotherapy but, instead, adds to the anti-tumor effect.
References	[1] https://pubmed.ncbi.nlm.nih.gov/26826116/ [2] https://pubmed.ncbi.nlm.nih.gov/33004541/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-05-06)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01042379	RECRUITING	Breast Neoplasms; Breast Cancer; Breast Tumors; Angiosarcoma; TNBC - Triple-Negative Breast Cancer; HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer	QuantumLeap Healthcare Collaborative	2010-03-01	PHASE2
NCT06698965	RECRUITING	Lung Cancer, Small Cell	Shanghai Chest Hospital	2024-10-13	PHASE2
NCT07736001	NOT_YET_RECRUITING	Tumor Patients	Tianjin Medical University Cancer Institute and Hospital	2026-07
NCT05874401	RECRUITING	Extensive-stage Small-cell Lung Cancer	Pharmacosmos A/S	2023-10-18	PHASE4
NCT07679997	NOT_YET_RECRUITING	Head & Neck Squamous Cell Carcinoma	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	2026-06-01	PHASE2
NCT07160283	NOT_YET_RECRUITING	Biliary Tract Neoplasms; Pancreatic Neoplasms	The Second Affiliated Hospital of Shandong First Medical University	2025-09-01	PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):